Portage Biotech (NASDAQ:ALP) Stock: Insider Fiorenzo Villani Purchases 5,150 Shares

Posted by Donald Scott on Oct 15th, 2026

Portage Biotech Inc. (NASDAQ:ALP – Get Free Report) insider Fiorenzo Villani acquired 5,150 shares of Portage Biotech stock in a transaction on Wednesday, October 7th. The shares were bought at an average cost of $3.80 per share, with a total value of $19,570.00. Following the completion of the transaction, the insider owned 54,036 shares of the company’s stock, valued at approximately $205,336.80. This trade represents a 10.53% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Fiorenzo Villani also recently made the following trade(s):

On Tuesday, September 22nd, Fiorenzo Villani acquired 10,000 shares of Portage Biotech stock. The stock was bought at an average price of $4.40 per share, for a total transaction of $44,000.00.
On Wednesday, September 16th, Fiorenzo Villani acquired 4,265 shares of Portage Biotech stock. The stock was bought at an average cost of $4.05 per share, for a total transaction of $17,273.25.
On Tuesday, September 15th, Fiorenzo Villani acquired 7,900 shares of Portage Biotech stock. The stock was bought at an average cost of $4.15 per share, for a total transaction of $32,785.00.
On Tuesday, September 15th, Fiorenzo Villani bought 10,382 shares of Portage Biotech stock. The shares were bought at an average price of $4.07 per share, with a total value of $42,254.74.
On Monday, September 14th, Fiorenzo Villani bought 2,000 shares of Portage Biotech stock. The shares were bought at an average price of $4.16 per share, with a total value of $8,320.00.
On Wednesday, September 9th, Fiorenzo Villani bought 7,000 shares of Portage Biotech stock. The shares were bought at an average cost of $5.07 per share, with a total value of $35,490.00.

Portage Biotech Stock Performance

Shares of ALP opened at $3.76 on Thursday. Portage Biotech Inc. has a 52 week low of $3.20 and a 52 week high of $351.75. The firm’s 50-day simple moving average is $6.15 and its 200 day simple moving average is $12.50. The company has a current ratio of 0.31, a quick ratio of 0.31 and a debt-to-equity ratio of 0.01.

Portage Biotech (NASDAQ:ALP – Get Free Report) last released its quarterly earnings results on Thursday, July 16th. The company reported $23.75 earnings per share for the quarter. The company had revenue of $0.05 million during the quarter. Sell-side analysts forecast that Portage Biotech Inc. will post -14.00 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ALP. Wall Street Zen upgraded Portage Biotech to a “hold” rating in a research note on Saturday, September 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Portage Biotech in a research note on Friday, July 24th. Zacks Research upgraded Portage Biotech to a “hold” rating in a research note on Tuesday, August 18th. Finally, HC Wainwright initiated coverage on Portage Biotech in a report on Monday, August 17th. They issued a “neutral” rating and a $12.50 price objective on the stock. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $12.50.

Check Out Our Latest Stock Analysis on Portage Biotech

Portage Biotech Company Profile

(Get Free Report)

Portage Biotech Inc is a clinical-stage biotechnology company focused on developing immuno-oncology therapies for patients with solid tumors. The company’s approach is designed to stimulate the immune system and directly target tumor cells, with the goal of addressing cancers that are resistant or unresponsive to existing treatments.

Portage’s lead investigational product is INT230-6, an intratumoral therapy based on a proprietary formulation designed to deliver anticancer agents directly into tumors.